As expected, President Trump nominated Alex Azar, a former Eli Lilly & Co. executive and Department of Health and Human Services official to the top post at HHS. The announcement was followed by a slew of accolades from medtech and health-care stakeholders. But Democrats in Congress are signaling plans to oppose the nomination.
One of the first to laud Azar's nomination was AdvaMed CEO Scott Whitaker who urged the Senate to confirm Azar...